Novo Nordisk maintains outperform with $156 target By Investing.com

On Friday, BMO Capital maintained its positive stance on Novo Nordisk (NYSE: NVO ), reiterating an Outperform rating and a $156.00 price target for the pharmaceutical giant. The firm's analyst highlighted the anticipated benefits to Novo No
Read more...